Mercer Global Advisors
AXSM icon

Mercer Global Advisors’s Axsome Therapeutics AXSM Stock Holding History

Mercer Global Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Sell
2,259
-963
-30% -$166K ﹤0.01% 2204
2025
Q4 		$588K Buy
3,222
+1,260
+64% +$176K ﹤0.01% 1758
2025
Q3 		$238K Buy
+1,962
New +$221K ﹤0.01% 2258

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors's AXSM Position: Q1 2026 in Review

Mercer Global Advisors reduced its Axsome Therapeutics (AXSM) stake by 30% in Q1 2026, selling an estimated $166K and leaving 2,259 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #2204.

Mercer Global Advisors first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $588K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Mercer Global Advisors held 2,259 shares of Axsome Therapeutics worth $382K as of Q1 2026.
  • Mercer Global Advisors sold 963 Axsome Therapeutics shares in Q1 2026, an estimated $166K.
  • Axsome Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2204 holding.
  • Mercer Global Advisors first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Mercer Global Advisors's Axsome Therapeutics position peaked at $588K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.